Advances in HIV Vaccine Development

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "HIV Vaccines".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 135

Special Issue Editor

Department of Medicine, Division of Infectious Diseases, Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY, USA
Interests: HIV; influenza; Ebola; coronavirus; vaccine; broadly neutralizing antibody and IgA

Special Issue Information

Dear Colleagues,

Upon infection, HIV integrates into the host human genome and cannot be cleared with current treatments. Hence, sterile prevention—a high bar for vaccine development—remains of the utmost importance to halt virus spread and disease. HIV infection is also chronic, leading to the accumulation of enormous viral genetic diversity and multifaceted immune evasion, such as trimer packaging, glycan shield, conformational dynamics, and the immunodorminance of non-neutralizing epitopes, to name a few on the HIV envelope glycoprotein. These properties render HIV one of the most difficult viruses for vaccine development. Although neutralizing epitopes have been mapped to almost the entire surface of the HIV envelope, broadly neutralizing antibodies present numerous challenging traits and have not been induced with current vaccines.

In this Special Issue, all studies and reviews that shed new light on both prophylactic and therapeutic HIV vaccines are welcome.

Dr. Xueling Wu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • HIV
  • envelope glycoprotein
  • vaccine
  • adjuvant
  • antibody
  • neutralization
  • ADCC
  • ADCP
  • complement
  • cellular immune response

Published Papers

This special issue is now open for submission.
Back to TopTop